A new urine-based test has improved prostate cancer detection compared to traditional methods, says a study.

The test, developed at the University of Michigan Comprehensive Cancer Center in the US, is called Mi-Prostate Score, or MIPS. While traditional prostate cancer detection models are based on prostate serum antigen, or PSA, levels, the new method combines PSA with two markers for prostate cancer, both of which can be detected through a urine sample.

“Around 50 percent of men who undergo a prostate biopsy do not have cancer. We need better ways to manage elevated PSA and determine who really needs to have a biopsy. MIPS gives men and their doctors better information to help make those decisions,” said lead study author Scott Tomlins, assistant professor at University of Michigan Medical School.

The study looked at around 2,000 men who were undergoing prostate biopsy because of elevated PSA levels. Using urine samples, the researchers conducted MIPS testing and compared results.

“MIPS gives men a more individualised risk assessment for prostate cancer, so that men concerned about their serum PSA levels can have a more informed conversation with their doctor about next steps in their care,” Tomlins said.

The test has been available clinically since September 2013. The findings appeared in the journal European Urology.

For more interesting stories, visit our Health page. Read more about Diseases & Conditions here.

Source: IANS

A lifestyle writer & editor for 8 years, Avantika Kukreti is a multi-platform media professional and has worked with some of the biggest media brands of India. She is fascinated by the dynamics of the social media and feels it’s the most-reliable news source in today’s times, if used wisely. Her recent three year stint in Shanghai has made her more health savvy after she watched the Chinese go lengths to maintain their fitness. When not working, she spends time watching Tom and Jerry, & Pocoyo re-runs with her daughter.